David R. Riley - Publications, H-index & Citations

David R. Riley

university of liverpool

33H指数

173论文数

7.5K被引数

收录论文 59

发表时间

Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes 代谢性肥胖手术与司美格鲁肽对代谢功能障碍相关脂肪性肝病患者及2型糖尿病患者不良肝脏及肝外结局的差异化影响

diabetes, obesity and metabolism

IF0

2026-04-13

OAAI

Weronika Stupalkowska; Alex E. Henney; David R. Riley; Eric G. Sheu; Uazman Alam; Daniel J. Cuthbertson

Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri-Menopausal MASLD 激素替代疗法对围绝经期MASLD患者肝脏和心血管代谢结局的影响

Liver International

IF5.2

2026-02-23

OAAI

Alex E. Henney; Jo Wilson; David R. Riley; Uazman Alam; Daniel J. Cuthbertson

Long-term adverse multi-system health outcomes of gestational diabetes mellitus: an analysis of real-world cohort data 妊娠糖尿病的长期多系统不良健康结局：一项真实世界队列数据分析

Diabetes Research and Clinical Practice

IF7.4

2026-02-21

OAAI

Megan O. Heague; Alex E. Henney; David R. Riley; Matthew Anson; Claire L Meek; Uazman Alam; Daniel J. Cuthbertson

Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study 针对Tirzepatide、Semaglutide和SGLT2抑制剂在2型糖尿病伴痴呆患者中的目标试验模拟：一项回顾性队列研究的真实世界证据

Diabetes Research and Clinical Practice

IF7.4

2026-01-14

PREAI

Alhena Younis; Alex E. Henney; David R. Riley; Matthew Anson; Sizheng S. Zhao; Gema H. Ibarburu; Rayaz A Malik; Li Su; Gregory Y.H. Lip; Daniel J. Cuthbertson; Uazman Alam

Clinical characteristics, prescribing patterns and outcomes in individuals with heart failure and type 1 diabetes versus type 2 diabetes

European Heart Journal

IF35.6

2025-11-05

PREAI

Y J Liew; D Riley; M Win; M Hussain; C C Lang; U Alam; I Mordi

Synergistic associations of metformin and GLP-1 receptor agonist use with adiposity-related cancer incidence in people living with type 2 diabetes 二甲双胍和GLP-1受体激动剂联用与肥胖相关癌症发病率在2型糖尿病患者中的协同关联

Diabetes, Obesity and Metabolism

IF0

2025-11-03

OAAI

Alex E. Henney MBChB; Megan Heague MBChB; David R. Riley MBChB; Theresa J. Hydes PhD; Matthew Anson MBChB; Uazman Alam PhD; Daniel J. Cuthbertson PhD

Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach GLP-1和GLP-1/GIP受体激动剂在预防酒精使用障碍方面的相对疗效：采用目标试验模拟方法

Diabetes, Obesity and Metabolism

IF0

2025-10-07

OAAI

Alex E. Henney MBChB; David R. Riley MBChB; Megan Heague MBChB; Carl A. Roberts PhD; Theresa J. Hydes PhD; Matthew Anson MBChB; David M. Hughes PhD; Uazman Alam PhD; Daniel J. Cuthbertson PhD

Spinal cord stimulation for the treatment of painful diabetic neuropathy and risk of major adverse cardiovascular events, mortality, amputation, infection and suicide: a retrospective cohort study 脊髓电刺激治疗痛性糖尿病神经病变及主要不良心血管事件、死亡率、截肢、感染和自杀风险：一项回顾性队列研究

eClinicalMedicine

IF10

2025-09-26

PREAI

Alex E. Henney; Bernhard Frank; David R. Riley; Matthew Anson; Jamie Burgess; Gema Hernadez; Gregory Y.H. Lip; Rayaz A. Malik; Solomon Tesfaye; Daniel J. Cuthbertson; Uazman Alam

Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes 目标试验模拟GLP-1和双重GLP-1/GIP激动剂以减少2型糖尿病中的主要不良肝脏结局

Liver International

IF5.2

2025-09-22

OAAI

Alex E. Henney; David R. Riley; Matthew Anson; Shazli Azmi; Uazman Alam; Daniel J. Cuthbertson

The impact of insulin pump therapy compared to multiple daily injections on complications and mortality in type 1 diabetes: A real-world retrospective cohort study 胰岛素泵治疗与每日多次注射相比对1型糖尿病并发症和死亡率的影响: 一项真实世界回顾性队列研究

DIABETES OBESITY & METABOLISM

IF5.7

2025-05-19

OAAI

Sophie Haughton MBChB; David Riley MBBS; Simon Berry MBChB (Hons); Muhammad Fahad Arshad MRCP; Aikaterini Eleftheriadou MBBS

The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study (vol 22, 574, 2024)抗血小板药物对非酒精性脂肪肝（NAFLD）患者癌症发病率化学保护作用：一项回顾性队列研究（卷 22，574，2024）

BMC MEDICINE

IF8.3

2025-03-31

OAAI

Anson, Matthew; Poon, Jun Shang; Henney, Alex E.; Riley, David; Ibarbaru, Gema H.; Sieberhagen, Cyril; Cuthbertson, Daniel J.; Alam, Uazman; Hydes, Theresa

Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis

CLINICAL THERAPEUTICS

IF3.6

2025-02-01

OAAI

Zhao, Sizheng Steven; Riley, David; Hernandez, Gema; Alam, Uazman

Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data

THORAX

IF7.7

2024-12-07

OAAI

Henney, Alex E.; Riley, David R.; Hydes, Theresa J.; Anson, Matthew; Ibarburu, Gema H.; Frost, Frederick; Alam, Uazman; Cuthbertson, Daniel J.

The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study

BMC MEDICINE

IF8.3

2024-12-03

OAAI

Anson, Matthew; Poon, Jun Shang; Henney, Alex E.; Riley, David; Ibarbaru, Gema H.; Sieberhagen, Cyril; Cuthbertson, Daniel J.; Alam, Uazman; Hydes, Theresa

The cumulative impact of type 2 diabetes and obstructive sleep apnoea on cardiovascular, liver, diabetes-related and cancer outcomes

DIABETES OBESITY & METABOLISM

IF5.7

2024-11-11

OAAI

Riley, David R.; Henney, Alex; Anson, Matthew; Hernadez, Gema; Zhao, Sizheng S.; Alam, Uazman; Wilding, John P. H.; Craig, Sonya; Cuthbertson, Daniel J.

Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on diabetic eye complications. Reply to Tsai Y-H, Hemphill NO, Kurth T 在评估SGLT2抑制剂和GLP-1受体激动剂对糖尿病性眼病并发症的影响时，讨论方法学考虑。回复蔡Y H，Hemphill NO，Kurth T

DIABETOLOGIA

IF10.2

2024-11-07

PREAI

Eleftheriadou, Aikaterini; Riley, David; Zhao, Sizheng S.; Austin, Philip; Hernandez, Gema; Lip, Gregory Y. H.; Jackson, Timothy L.; Wilding, John P. H.; Alam, Uazman

SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum

CLINICAL THERAPEUTICS

IF3.6

2024-11-01

OAAI

Preston, Frank G.; Anson, Matthew; Riley, David R.; Ibarburu, Gema H.; Henney, Alexander; Lip, Gregory Y. H.; Cuthbertson, Daniel J.; Alam, Uazman; Zhao, Sizheng S.

Metabolic syndrome traits differentially and cumulatively influence micro- and macrovascular disease risk in patients with MASLD

LIVER INTERNATIONAL

IF5.2

2024-09-02

OAAI

Henney, Alex E.; Riley, David R.; Hydes, Theresa J.; Anson, Matthew; Ibarburu, Gema H.; Zhao, Sizheng S.; Cuthbertson, Daniel J.; Alam, Uazman

Sodium-glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real-world, cohort data

DIABETES OBESITY & METABOLISM

IF5.7

2024-08-07

OAAI

Henney, Alex E.; Riley, David R.; Heague, Megan; Hydes, Theresa J.; Anson, Matthew; Alam, Uazman; Cuthbertson, Daniel J.

Risk of Type 2 Diabetes, MASLD and Cardiovascular Disease in People Living With Polycystic Ovary Syndrome

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2024-07-11

OAAI

Henney, Alex E.; Gillespiec, Conor S.; Lai, Jonathan Y. M.; Schofield, Pieta; Riley, David R.; Caleyachetty, Rishi; Barber, Thomas M.; Miras, Alexander D.; Dobbie, Laurence J.; Hughes, David M.; Alam, Uazman; Hydes, Theresa J.; Cuthbertson, Daniel J.

研究方向